To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma

Inclusion Criteria

• •1. Male or female, age ≥ 20 years old.
• •2. Patient who accepts to enter the study by signing written informed consent.
• •3. Patient with performance status ≤ 2 Eastern Cooperative Oncology Group (ECOG).
• •4. Patient with cirrhosis or chronic liver diseases suspected to have at least 1 hepatic nodule larger than 1 cm in diameter detected by conventional image (US, CT, MRI). Patient who has not yet received any therapy relevant to the aforementioned diagnosis. Hepatic nodule is defined as any one of the following conditions: suspicious hepatocellular carcinoma, benign tumor such as hemangioma, adenoma or focal nodular hyperplasia, metastatic lesions from other primary malignancy.
• •5. Female patient must take reliable contraception method(s) during the participation of the study.